Esteban Cvitkovic
Overview
Explore the profile of Esteban Cvitkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Astorgues-Xerri L, Vazquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, et al.
Leuk Lymphoma
. 2019 Jun;
60(12):3067-3070.
PMID: 31204545
No abstract available.
2.
Civenni G, Bosotti R, Timpanaro A, Vazquez R, Merulla J, Pandit S, et al.
Cell Metab
. 2019 May;
30(2):303-318.e6.
PMID: 31130467
Cancer stem cells (CSCs) contribute to disease progression and treatment failure in human cancers. The balance among self-renewal, differentiation, and senescence determines the expansion or progressive exhaustion of CSCs. Targeting...
3.
Tarantelli C, Bernasconi E, Gaudio E, Cascione L, Restelli V, Arribas A, et al.
ESMO Open
. 2018 Oct;
3(6):e000387.
PMID: 30305939
Background: The outcome of patients affected by mantle cell lymphoma (MCL) has improved in recent years, but there is still a need for novel treatment strategies for these patients. Human...
4.
Vazquez R, Riveiro M, Astorgues-Xerri L, Odore E, Rezai K, Erba E, et al.
Oncotarget
. 2016 Dec;
8(5):7598-7613.
PMID: 27935867
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted...
5.
Riveiro M, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, et al.
Oncotarget
. 2016 Nov;
7(51):84675-84687.
PMID: 27835869
Inhibitors targeting epigenetic control points of oncogenes offer a potential mean of blocking tumor progression in small cell and non-small cell lung carcinomas (SCLC, NSCLC). OTX015 (MK-8628) is a BET...
6.
Boi M, Todaro M, Vurchio V, Yang S, Moon J, Kwee I, et al.
Oncotarget
. 2016 Oct;
7(48):79637-79653.
PMID: 27793034
Anaplastic large cell lymphomas (ALCL) represent a peripheral T-cell lymphoma subgroup, stratified based on the presence or absence of anaplastic lymphoma kinase (ALK) chimeras. Although ALK-positive ALCLs have a more...
7.
Vazquez R, Licandro S, Astorgues-Xerri L, Lettera E, Panini N, Romano M, et al.
Int J Cancer
. 2016 Sep;
140(1):197-207.
PMID: 27594045
It has recently been reported that a large proportion of human malignant pleural mesothelioma (MPM) cell lines and patient tissue samples present high expression of the c-MYC oncogene. This gene...
8.
Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, et al.
Oncotarget
. 2016 Aug;
7(36):58142-58147.
PMID: 27494885
The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and clinical settings, as well as in vitro synergism with several anticancer agents....
9.
Berenguer-Daize C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, et al.
Int J Cancer
. 2016 Jul;
139(9):2047-55.
PMID: 27388964
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on chromatin, acting as co-activators or co-repressors of gene expression. BRD2 and BRD4, members...
10.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al.
Clin Cancer Res
. 2015 Dec;
22(10):2470-81.
PMID: 26631615
Purpose: Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models...